tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Michael Ulz, 102 are a BUY (61.08%), 59 are a HOLD (35.33%), 6 are a SELL (3.59%).
Analyst Michael Ulz, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 55.05% that have a potential upside of 42.9% achieved within 170 days.
Michael Ulz’s has documented 376 price targets and ratings displayed on 39 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on IONS, Ionis Pharmaceuticals at 31-Jul-2025.
Analyst best performing recommendations are on NRIX (NURIX THERAPEUTICS ).
The best stock recommendation documented was for CABA (CABALETTA BIO) at 8/30/2022. The price target of $3 was fulfilled within 76 days with a profit of $2.01 (203.03%) receiving and performance score of 26.71.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$205
$22.5 (12.33%)
4 years 3 months 1 days ago
(05-May-2021)
3/5 (60%)
$35.09 (20.65%)
938
Hold
$173
$-9.5 (-5.21%)
$156
4 years 3 months 3 days ago
(03-May-2021)
14/24 (58.33%)
$2.73 (1.60%)
682
Hold
$190
4 years 3 months 11 days ago
(26-Apr-2021)
9/11 (81.82%)
$34.41 (22.12%)
350
Hold
$166
$-16.5 (-9.04%)
$175
4 years 6 months 2 days ago
(04-Feb-2021)
23/23 (100%)
$10.41 (6.69%)
828
Buy
$155
4 years 6 months 30 days ago
(07-Jan-2021)
7/7 (100%)
$36.79 (31.12%)
395
Which stock is Michael Ulz is most bullish on?
Which stock is Michael Ulz is most reserved on?
What Year was the first public recommendation made by Michael Ulz?
